Laboratorios Farmaceuticos Rovi SA
Fermé
SecteurSoins de santé
58.4
Résumé
Variation du prix de l'action
24h
Min
57.95
Max
58.5
Revenu | -33M 9.5M |
|---|---|
Ventes | -66M 152M |
P/E Moyenne du Secteur | 24.641 49.052 |
BPA | 0.185 |
Marge bénéficiaire | 6.216 |
Employés | 1,950 |
EBITDA | -45M 18M |
Recommandations | Achat |
|---|---|
Prévisions sur 12 Mois | +25.92% upside |
Prochains Résultats | 23 juil. 2026 |
|---|
Capitalisation Boursière | -1.1B 3B |
|---|---|
Ouverture précédente | 58.4 |
Clôture précédente | 58.4 |
Sentiment de l'Actualité
By Acuity
50%
50%
162 / 342 Classement par Healthcare
Laboratorios Farmaceuticos Rovi SA Graphique
Les performances passées ne sont pas un indicateur fiable des résultats futurs.
À Propos Laboratorios Farmaceuticos Rovi SA
Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.